Silihan lan utang jangka dawa perusahaan: enlivex.com (ENLV)

The primary risks for Enlivex Therapeutics (ENLV) are linked to the capital intensity of cell technologies and the complexity of combating sepsis. The business relies on developing macrophage reprogramming methods, which promises high margins upon mass production. Stability is ensured by a strong Israeli staff of scientists and the hiring of specialized managers. Debt stands at 0.00, which is reflected in the chart of the asset's value on the GURU.Markets platform.

This indicator captures the total volume of liabilities with maturities exceeding twelve months, allowing for an assessment of the issuer's long-term debt load and financial stability. By analyzing the dynamics of the firm's long-term borrowings, an investor can identify the resource base for scaling the R&D pipeline, which is critically important for Enlivex Therapeutics (ENLV) during the accelerated development of Allocetra drugs for sepsis and tumors.